Bicycle rides to $200M payday, while lung disease biotech raises $80M
Bicycle Therapeutics raised about $200 million through a public offering at $21.25 per share a few days before its new CFO is slated to step into her post.
The biotech’s shares $BCYC rose nearly 10% Thursday morning after the pricing, to just over $24 apiece.
The Cambridge, UK, and Boston biotech lined up two Big Pharma partnerships this year for about $95 million upfront. Its alliances with Bayer and Novartis revolve around targeted radiotherapies. — Kyle LaHucik
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
